ATEA PHARMACEUTICALS INC (AVIR)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for AVIR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AVIR | Lead Independent Director | 76 | ["Expertise in life science finance and capital markets","Experience leading equity research divisions at major investment banks","Founded investment research firms","Participated in significant life science sector financings","Extensive corporate governance experience from serving on numerous public biopharmaceutical company boards","Founder and Managing Director at FMB Research LLC (2005-present)","Co-Portfolio Manager at Sectoral Biotechnology Fund (2007-2008)","Founded the small-cap focused NEMO Fund at Sectoral Asset Management Inc. (2007-2008)","Managing Director, Head of Biotech Equity Research at JP Morgan Securities (1998-2003)","Managing Director, Head of Biotech Equity Research at Salomon Brothers (1997-1998)","Biotech Equity Research Analyst at Josephthal & Co. (1991-1997)"] | ["Audit","Compensation","Compensation (Chair)"] | 2026 |
Biography sourced from the proxy statement filing.
Franklin Berger Lead Independent Director Age: 76 Director Since: 2019* Class: I Committee Memberships Compensation (Chair) Audit Education John Hopkins University, BA John Hopkins University, MA Harvard Business School, MBA * Mr. Berger will not seek re-election when his current term ends at the 2027 annual meeting of stockholders. Qualifications and Expertise Provided to Our Board Mr. Berger provides deep expertise in life science finance and capital markets, drawing on decades of experience including leading equity research divisions at major investment banks including JP Morgan and Salomon Brothers, founding investment research firms, and participating in significant life science sector financings. Mr. Berger s financial acumen, coupled with extensive corporate governance experience from serving on numerous public biopharmaceutical company boards, significantly enhances the Board s oversight of the Company s strategy, operational execution and capital allocation. Professional Experience Founder and Managing Director at FMB Research LLC (2005-present) Co-Portfolio Manager at Sectoral Biotechnology Fund , a $7 billion investment fund (2007-2008) Founded the small-cap focused NEMO Fund at Sectoral Asset Management Inc. (2007-2008) Managing Director, Head of Biotech Equity Research at JP Morgan Securities , where he was involved with issuance of more than $12 billion in biotech/biopharmaceutical company equity or equity linked securities (1998-2003) Managing Director, Head of Biotech Equity Research at Salomon Brothers (1997-1998) Biotech Equity Research Analyst at Josephthal & Co. , where he led fundraising/underwriting groups (1991-1997) Other Public Company Directorships (past five years): Kezar Life Sciences, Inc. (Ticker: KZR), 2016-present Satellos Bioscience Inc. (Ticker: MSLE), 2023-present Atreca, Inc. (Ticker: BCEL), 2014-2024 Essa Pharma, Inc. (Ticker: EPIX), 2015-2025 Rain Therapeutics Inc. (Ticker: RAIN), 2020-2024 Bellus Health, Inc. (Ticker: BLU), 2010-2023 Five Prime Therapeutics, Inc. (Ticker: FPRX), 2014-2021 Core Skills Life Sciences / Healthcare Industry Business Development / Strategic Partnerships Finance & Audit M&A / Strategic Investments Senior Executive Role Corporate Governance